Reynders McVeigh Capital Management’s AstraZeneca AZN Stock Holding History

Reynders McVeigh Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-4,800	Closed	-$651K	–	204
2022 Q4	$651K	Hold	4,800	–	–	0.05%	117
2022 Q3	$526K	Hold	4,800	–	–	0.04%	135
2022 Q2	$634K	Sell	4,800 -34	-0.7%	-$4.46K	0.05%	126
2022 Q1	$641K	Sell	4,834 -46	-0.9%	-$5.52K	0.04%	137
2021 Q4	$568K	Buy	+4,880	New	+$574K	0.03%	154

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Reynders McVeigh Capital Management's AZN Position: Q1 2023 in Review

Reynders McVeigh Capital Management sold out of AstraZeneca (AZN) in Q1 2023, closing a stake of 4,800 shares — an estimated $651K sold.

Reynders McVeigh Capital Management first reported a position in AZN in Q4 2021 and held it in 5 quarters. The position peaked at $651K in Q4 2022. 1,054 funds tracked by Wall St. Rank hold AZN as of Q1 2023.

Reynders McVeigh Capital Management reported no remaining AstraZeneca position as of Q1 2023 after selling out during the quarter.
Reynders McVeigh Capital Management sold 4,800 AstraZeneca shares in Q1 2023, an estimated $651K.
Reynders McVeigh Capital Management first reported a position in AstraZeneca in Q4 2021 and held it in 5 quarters.
Reynders McVeigh Capital Management's AstraZeneca position peaked at $651K in Q4 2022.
1,054 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2023.

Based on Reynders McVeigh Capital Management's 13F filing for Q1 2023, filed 3 May 2023.